GSK Files NDA for Tykerb for Advanced Breast Cancer Rx

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

GlaxoSmith-Kline (GSK) has announced the submission of a New Drug Application to the US Food and Drug Administration (FDA) for approval to market Tykerb (lapatinib ditosylate), in combination with capecitabine (Xeloda), for the treatment of advanced or metastatic HER2-positive breast cancer

PHILADLEPHIA—GlaxoSmith-Kline (GSK) has announced the submission of a New Drug Application to the US Food and Drug Administration (FDA) for approval to market Tykerb (lapatinib ditosylate), in combination with capecitabine (Xeloda), for the treatment of advanced or metastatic HER2-positive breast cancer in women who have received prior therapy, including trastuzumab (Herceptin). The company has been granted Fast Track status by the FDA in this patient population. Tykerb, an oral small-molecule dual-kinase inhibitor, is currently being investigated in breast cancer and other solid tumors.

The filing is based on a planned interim analysis of the phase III international, multicenter, open-label trial presented at ASCO 2006 (see ONI June 2006, page 1). The trial included 324 women with advanced or metastatic breast cancer with documented HER2 overex­pression and whose disease progressed following treatment with Herceptin and other cancer therapies. They were randomized to receive Tykerb/Xeloda or Xeloda alone. The results showed that median time to progression was 8.5 months with the combination vs 4.4 months with Xeloda alone (P = .00008).

"This filing is the result of many years of tremendous research and development work by the scientists at GSK," said Paolo Paoletti, MD, senior vice president at GSK's Oncology Medicine Development Center. "It is truly an outstanding milestone, especially for the many thousands of women who are facing the devastating effects of advanced breast cancer. Many of these women are desperately in need of alternative treatments, and this filing shows that we have turned the corner toward a new era of targeted agents."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.